


RECEIVED
CENTRAL FAX CENTER**JUN 15 2005****CERTIFICATION OF FACSIMILE TRANSMISSION**

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

RENÉE Y. EDWARDS

Type or print name of person signing certification

 June 15, 2005
Signature Date

703 872 9306

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Rito, *et al.*)
Serial Number : 10/694,467)
Filed: : October 27, 2003) Group Art Unit:
For : SELECTIVE β 3 ADRENERGIC) 1625
AGONISTS) Examiner:
Docket No. : X-10909C) Morris, Patricia L.

TERMINAL DISCLAIMER UNDER 37 C.F.R. 1.321

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Identification of Person Making This Disclaimer

I, Gilbert T. Voy, am employed by Eli Lilly and Company, and I am an attorney of record in the above-identified patent application. In that capacity, I am authorized to sign this disclaimer on behalf of Eli Lilly and Company.

Identity of Assignee

I hereby verify that the assignee owning all of the interest in this application is:

Eli Lilly and Company
Lilly Corporate Center
Indianapolis, Indiana 46285

Recordal of Assignment in PTO

The assignment was recorded on December 19, 2000, Reel 011398, Frame

0966.

RECEIVED
CENTRAL FAX CENTER

JUN 15 2005

Serial No. 10/694,467

X10909C

Extent of Interest

The extent of Eli Lilly and Company's interest is in the whole of this invention.

Disclaimer

I hereby disclaim the terminal part of any patent granted on this application, which would extend beyond the expiration date of:

United States Patent No. 6,140,352 and hereby agree that any patent granted on this application shall be enforceable only for and during such period that the legal title to the patent shall be the same as the legal title to United States Patent No. 6,140,352.

I do not disclaim any terminal part of any patent granted on this application prior to the expiration date of the full statutory term of United States Patent No. 6,140,352 in the event that either of them later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321, has all claims cancelled by a reexamination certificate, or is otherwise terminated prior to expiration of its full statutory term other than as presently shortened by any terminal disclaimer.

I do not disclaim any term of a patent granted on this application that extends beyond United States Patent No. 6,140,352 in the event that the patent granted on this application is adjusted or extended under any of 35 U.S.C. §§154-156.

Serial No. 10/694,467

X10909C

Fee Payment

Please charge the fee as designated by the attached Fee Transmittal, the fee set forth in 37 C.F.R. 1.20(d), and charge any additional fees which may be required by this or any other related paper, or credit any overpayment to Deposit Account No. 05-0840 in the name of Eli Lilly and Company. Two copies of this disclaimer are enclosed.

ELI LILLY AND COMPANY

By: 

Gilbert T. Voy
Attorney for Applicant
Registration No. 43,972
Phone: 317-276-2966

Eli Lilly and Company
Patent Division/GTV
Lilly Corporate Center
Indianapolis, Indiana 46285

June 15 2005